Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $46.83

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have received a consensus rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $46.83.

DNTH has been the subject of several research analyst reports. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently modified their holdings of DNTH. Jane Street Group LLC purchased a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $556,000. Barclays PLC lifted its holdings in Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after buying an additional 33,185 shares during the period. HighVista Strategies LLC purchased a new position in Dianthus Therapeutics in the third quarter valued at about $542,000. State Street Corp grew its position in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Dianthus Therapeutics by 142.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after purchasing an additional 97,362 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

DNTH stock opened at $24.49 on Friday. Dianthus Therapeutics has a 1-year low of $18.34 and a 1-year high of $33.77. The business has a 50 day simple moving average of $22.93 and a two-hundred day simple moving average of $25.58. The company has a market capitalization of $724.90 million, a price-to-earnings ratio of -9.80 and a beta of 1.72.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.